Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the
“Company”), a biotechnology company focused on discovering and
developing novel antibody immunotherapies that help the immune system
fight cancer and other diseases, today announced that Arthur H.
Tinkelenberg, Ph.D., President and Chief Executive Officer, will present
a corporate overview at the Oppenheimer 26th Annual Healthcare
Conference on Tuesday, December 8th, 2015 at 3:20 p.m. ET at The Westin
New York Grand Central Hotel in New York City.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these
agents, Enumeral’s researchers apply a proprietary immune profiling
technology platform that measures functioning of the human immune system
at the level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151201005322/en/
Copyright Business Wire 2015